drugset / Trial / NCT01316302
12-Week Study of Pristiq (Desvenlafaxine) Social Anxiety Disorder
RandomizedParallel-groupTriple-blindTreatment
Summary
This study is designed to evaluate the efficacy and safety of Pristiq® in treatment of the symptoms of Generalized Social Anxiety Disorder (SAD).
Timeline
- Start
- 2011-04
- Primary completion
- 2012-11
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Desvenlafaxine | Other / unclassified | 50 mg | — |
| Subject | Desvenlafaxine | Other / unclassified | 100 mg | — |